Bluebird Bio gains on collaboration with Regeneron
In pre-market trading the shares of Bluebird Bio (BLUE) were last up 5.6% to $158.40 after announcing a collaboration with Regeneron Pharmaceuticals (REGN) in the pursuit of immune cell therapies for cancer treatment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.